Intellectual Property Law and Copyright Laws

In a collaborative effort, the European Union Intellectual Property Office (EUIPO), the European Commission, and the European Union Intellectual Property Network (EUIPN) have launched a groundbreaking initiative to foster innovation and growth across the European Union.

Par un instrument déposé le 3 juin 2025, le Commonwealth des Bahamas a formellement adhéré au Traité de Budapest du 28 avril 1977, modifié le 26 septembre 1980...

Producenten die traditionele producten uit een regio maken (denk aan Limburgse vlaai), hebben een nieuw juridisch instrument om hun producten te beschermen tegen namaak...

In business, even the simplest of arrangements benefit from being set out clearly in writing. A well-drafted contract not only clarifies the terms of the agreement...

Merger and acquisition (M&A) activities present many challenges to buyers and sellers, particularly when it comes to intellectual property (IP) issues.

Trade secrets are among a company's most valuable assets, safeguarding competitive advantages in industries ranging from technology to manufacturing.

In 2024, Lidl secured a win in a high-profile trademark dispute in the United Kingdom.

The rise of e-commerce has made it easier than ever for counterfeit goods to circulate across Europe.

La Cour d'appel d'Aix-en-Provence a rendu le 23 avril 2025 un arrêt rappelant la règle en matière de prescription de l'action en contrefaçon de droit d'auteur dans une affaire opposant deux sculpteurs.

On 9 February 2012, the Court of Justice of the European Union (the "ECJ") answered a preliminary question referred to it by the High Court of Justice of England and Wales (the "Referring Court") in Novartis AG ("Novartis") v. Actavis UK Ltd.

A recently published decision of the European Patent Office’s (EPO) Board of Appeal about European patents and clinical trials provides for interesting reading and for some important pointers about how to deal with clinical trials for medicinal products but also for medical devices as to not destroy novelty of a patentable invention with invalidity as result.

The patent of Oliver Brüstle that is at stake relates to purified neural precursor cells and to processes for their production from embryonic stem cells.